Elafibranor

N/A

Report date: 2026/05/07 20:00:36
NME

Base Information

Drug NameElafibranor
Drug Alias NameElafibranorum依拉雷诺依非兰诺IqirvoGFT-505 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPeroxisome proliferator-activated receptor delta agonistsPeroxisome proliferator-activated receptor α agonists
TargetsPeroxisome proliferator-activated receptor αPeroxisome proliferator-activated receptor delta
Therapy Area/IndicationsObesity, AbdominalObesityDyslipidemias +[16] 
Global Approved IndicationsCholangitis, SclerosingLiver Cirrhosis, Biliary
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2024/06/10
Country/TerritoryCzechiaBelgiumBosnia and Herzegovina +[45] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesGenfit Corp
China Registration ClassN/A

Develop Information

Active CompaniesIpsenIpsen PharmaIpsen Biopharm Ltd +[4] 
Inactive CompaniesGenfit Corp
Active IndicationsMetabolic Dysfunction-Associated Steatotic Liver DiseaseCholangitis, SclerosingLiver Cirrhosis, Biliary
Inactive IndicationsObesity, AbdominalObesityDyslipidemias +[13] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG